Analysts See Alnylam Pharmaceuticals Inc. (ALNY) Rising 20.23%

Publicly-traded company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) had a closing price of $91.74 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $115.00, this means that the stock is underpriced by 20.23%. In the past 52 weeks the company’s stock price has moved within the range of $60.27 to $96.08.

This particular stock’s 5-day moving average is 88.99, its 20-day moving average is 84.82 and its 100-day moving average is 79.31. Alnylam Pharmaceuticals Inc. (ALNY) currently has 105.99M shares outstanding, which means that its market capitalization is $9.72B.

The Details: Alnylam Pharmaceuticals Inc. (ALNY) Financial Health

Return on Assets is a number, expressed as a percentage that tells us how well a publicly-traded company is using its current assets to generate revenue. The higher the percentage, the better a company is using its assets to turn a profit. At the moment, Alnylam Pharmaceuticals Inc. Return on Assets is -43.00%.

What Does Wall Street Say about Company?

When choosing stocks, many investors search for what Wall Street professionals think about the company first – like what the average rating is. At the moment, the average analyst rating for ALNY is Overweight. Out of 19 total analysts who were surveyed, 1 rated it a sell, 0 rated it a underweight, 1 rated it an overweight, 4 rated it hold, and 13 rated it a Buy.

Three months ago, on the other hand, the average analyst rating for Alnylam Pharmaceuticals Inc. (ALNY) was a Overweight – from a survey of 19 analysts. Of the analysts who provided ratings, 3 rated the company a Hold, 1 rated it a Sell, 2 rated it an overweight, 0 rated it an underweight, and 13 rated it a Buy.

Understanding Profitability at Alnylam Pharmaceuticals Inc. (ALNY)

Taking a look at a public company’s Earnings per Share (EPS) is a good way of evaluating its profitability. In the most recent financial results released by Alnylam Pharmaceuticals Inc., for the quarter ending on 12/2019, the company posted EPS of -2.29. The average estimate of Wall Street analysts had projected -2.08.

Wall Street analysts, on average, are forecasting the company’s EPS to be -2.17, compared to -2.09 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 16 analysts is 69.15M – compared to 21.03M posted in the year-ago period.